评价经动脉化疗栓塞术（TACE）联合瑞戈非尼（以下简称TACE-瑞戈非尼）或卡瑞利珠单抗（以下简称TACE-卡瑞利珠单抗）治疗TACE和索拉非尼治疗后进展无法治愈的肝细胞癌（HCC）的有效性和安全性。病历对 2018 年 9 月至 2023 年 12 月期间接受 TACE-瑞戈非尼或 TACE-卡瑞珠单抗的 HCC 患者进行回顾性评估。比较两组的治疗反应、总生存期（OS）、无进展生存期（PFS）和不良事件（AE）。本研究共有76名患者入组，其中TACE患者分别为41名和35名。分别为瑞戈非尼组和 TACE-卡瑞珠单抗组。 TACE-瑞戈非尼组和TACE-卡瑞珠单抗组的客观缓解率分别为9.8%和8.6%，两组之间无统计学差异（P = 0.859）。同样，两组疾病控制率差异无统计学意义（61.0% vs 68.6%，P = 0.838）。 TACE-瑞格非尼组的中位 OS 为 11 个月，TACE-卡瑞利珠单抗组的中位 OS 为 10 个月，两组之间无显着差异 (P = 0.348)。 TACE-瑞戈非尼组的中位 PFS 为 7 个月，明显长于 TACE-卡瑞利珠单抗组（4 个月，P = 0.004）。两组之间的 AE 发生率无显着差异（P = 0.544）。TACE-瑞戈非尼安全、耐受性良好，并且在索拉非尼难治性晚期 HCC 患者中显示出良好的疗效，而 TACE-卡瑞利珠单抗则表现出相似的生存率好处。

To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with regorafenib (hereafter, TACE-regorafenib) or camrelizumab (hereafter, TACE-camrelizumab) for treating hepatocellular carcinoma (HCC) with untreatable progression after TACE and sorafenib therapy.The medical records of patients with HCC who received TACE-regorafenib or TACE-camrelizumab between September 2018 and December 2023 were retrospectively evaluated. Therapeutic response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups.A total of 76 patients were enrolled in this study, with 41 and 35 patients in the TACE-regorafenib and TACE-camrelizumab groups, respectively. The objective response rates in the TACE-regorafenib and TACE-camrelizumab groups were 9.8% and 8.6%, respectively, with no statistically significant difference between the two groups (P = 0.859). Similarly, there was no statistically significant difference in disease control rates between the two groups (61.0% vs 68.6%, P = 0.838). The median OS was 11 months in the TACE-regorafenib group and 10 months in the TACE-camrelizumab group, with no significant difference between the two groups (P = 0.348). The TACE-regorafenib group had a median PFS of 7 months, which was significantly longer than that of the TACE-camrelizumab group (4 months, P = 0.004). There was no significant difference in the incidence of AEs between the two groups (P = 0.544).TACE-regorafenib was safe, well-tolerated, and showed promising efficacy in patients with sorafenib-refractory advanced HCC, whereas TACE-camrelizumab demonstrated similar survival benefits.